- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07937865
Early Intervention for Postpartum PTSD: Comparing Written Exposure and Capnometry-Guided Breathing Therapy - Phase 2
Early Intervention for Postpartum PTSD: Comparing Written Exposure and Capnometry Guided Breathing Therapy - Phase 2
The purpose of this study is to evaluate the feasibility, acceptability, and preliminary effectiveness of two early interventions, Written Exposure Therapy (WET) and Capnometry-Guided Breathing Intervention (CGRI), for reducing post-traumatic stress disorder (PTSD) symptoms following childbirth, compared with usual care.
Przegląd badań
Status
Warunki
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Arkansas
-
Little Rock, Arkansas, Stany Zjednoczone, 72205
- University of Arkansas for Medical Sciences
-
Kontakt:
- Heather Moody
- Numer telefonu: 501-526-4333
- E-mail: HLMoody@uams.edu
-
-
California
-
Palo Alto, California, Stany Zjednoczone, 94304
- Stanford University
-
Kontakt:
- Guillermina Ferrea
- Numer telefonu: (650) 457 7704
- E-mail: gferrea@stanford.edu
-
Kontakt:
- Aleesha Jethwa
- Numer telefonu: +44 7857 907762
- E-mail: Ajethwa1@stanford.edu
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Age ≥18
- Delivered a live infant within 5 days
- Severe maternal morbidity or infant admitted to NICU
- PCL-5 ≥28
- English-speaking
- Able to consent and participate
Exclusion Criteria:
- Active psychosis or mania
- Current suicidal crisis
- Current suicidal intent or plan
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Written Exposure Therapy (WET)
Participants will complete 5 writing sessions. One 50-minute session will be held in the hospital before discharge, followed by four 50-minute sessions by secure video once a week. Sessions are delivered by a trained study therapist under licensed clinician supervision. |
Participants will complete 5 writing sessions. One 50-minute session will be held in the hospital before discharge, followed by four 50-minute sessions by secure video once a week. Sessions are delivered by a trained study therapist under licensed clinician supervision. |
|
Eksperymentalny: Capnometry-Guided Breathing Intervention (CGRI)
Participants will complete one 45-minute in-hospital training session using the device, which includes a tablet and breathing sensor. They will then practice guided breathing at home twice daily for about 17 minutes each time for 4 weeks, with weekly phone check-ins from study staff. |
Participants will complete one 45-minute in-hospital training session using the device, which includes a tablet and breathing sensor. They will then practice guided breathing at home twice daily for about 17 minutes each time for 4 weeks, with weekly phone check-ins from study staff. |
|
Brak interwencji: Postpartum Standard of Care
Participants will follow their current standard of care. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Odsetek uczestników ukończających Terapię Ekspozycji Pisemnej (WET)
Ramy czasowe: Od wartości wyjściowej do 6. tygodnia
|
Od wartości wyjściowej do 6. tygodnia
|
|
|
Procent przestrzegania terapii ekspozycji pisemnej (WET)
Ramy czasowe: Od wartości początkowej do 6. tygodnia
|
Od wartości początkowej do 6. tygodnia
|
|
|
Odsetek uczestników ukończających interwencję oddechową z kapnometrią (CGRI)
Ramy czasowe: Od wartości wyjściowej do 6. tygodnia
|
Od wartości wyjściowej do 6. tygodnia
|
|
|
Procentowa zgodność z interwencją oddechową pod kontrolą kapnometrii (CGRI)
Ramy czasowe: Od wartości wyjściowej do 6. tygodnia
|
Od wartości wyjściowej do 6. tygodnia
|
|
|
Percentage of participants initiating assigned treatment
Ramy czasowe: Baseline (up to 2 weeks)
|
Proportion of participants who begin their assigned intervention (≥1 session for WET; completion of initial training for CGRI) |
Baseline (up to 2 weeks)
|
|
Participant Satisfaction Scale Score using Client Satisfaction Questionnaire (CSQ-8)
Ramy czasowe: Week 5
|
Participant satisfaction measured using the CSQ-8 questionaire, an 8-item scale. (Scale score 8 - 32. Higher scores represent greater satisfaction with treatment.) |
Week 5
|
|
Treatment credibility using the Opinion About Treatment (OAT) form
Ramy czasowe: Week 5
|
Participant perceptions of treatment credibility will be measured using the OAT form. (Scale score 3 - 27. Higher scores represent greater perceived credibility of the intervention.) |
Week 5
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change from baseline in PTSD Checklist for DSM-5 (PCL-5) Scale Score
Ramy czasowe: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 12
|
Change in PTSD symptoms during past week measured by the PTSD Checklist for DSM-5 (PCL-5), a 20-item self-report measure. (Score range 0 - 80, higher scores indicating greater severity of PTSD symptoms.). |
Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 12
|
|
Change from baseline in Edinburgh Postnatal Depression Scale (EPDS) Scale Score
Ramy czasowe: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 12
|
Participants complete the EPDS questionnaire, a 10-item scale assessing postpartum depressive symptoms over the past 7 days. (Score range 0 - 30, higher scores represents greater symptom severity.) |
Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 12
|
|
Change from baseline in Whole Person Health Index (WPHI) Scale Score
Ramy czasowe: Baseline, Week 3, Week 6, Week 12
|
Participants complete WHPI questionaire, a 9 item scale assessing global health and functioning. (Score range 9 - 81, higher scores represent better health). |
Baseline, Week 3, Week 6, Week 12
|
|
Change from baseline in Generalized Anxiety Disorder Questionaire (GAD-7)
Ramy czasowe: Baseline, Week 3, Week 6, Week 12
|
Participants complete the GAD-7, a 7-item scale assessing anxiety symptoms over 2 weeks. (Score range 0 - 21, higher scores represent greater anxiety severity.) |
Baseline, Week 3, Week 6, Week 12
|
|
Change from baseline in Maternal-infant bonding (MIBS) Scale Score
Ramy czasowe: Baseline, Week 3, Week 6, Week 12
|
Participants complete the MIBS questionaire, an 8 item measure of bonding difficulties over the past few weeks (Score range 0 - 24, higher scores represent greater bonding impairment). |
Baseline, Week 3, Week 6, Week 12
|
|
Change from baseline in STanford Obstetric Recovery checKlist (STORK) scale score
Ramy czasowe: Baseline, Week 3, Week 6, Week 12
|
Participants complete the STORK questionnaire, a 47-item scale assessing postpartum recovery over the past 7 days. (Score range 0 - 188, higher score represents a greater degree of recovery) |
Baseline, Week 3, Week 6, Week 12
|
|
Change from baseline in Breastfeeding Self-Efficacy Scale-Short Form (BFSES-SF)
Ramy czasowe: Baseline, Week 3, Week 6, Week 12
|
Participants complete the BFSES-SF, a 14-item measure of breastfeeding self-efficacy (Score range 14 - 70, higher scores indicate greater breastfeeding confidence.) |
Baseline, Week 3, Week 6, Week 12
|
|
Percentage of participants completing hair sample collection at Baseline and Week 6
Ramy czasowe: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. |
Baseline, Week 6
|
|
Change in hair cortisol concentration between Baseline and Week 6
Ramy czasowe: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair cortisol concentration from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair cortisone concentration between Baseline and Week 6
Ramy czasowe: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair cortisone concentration from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair testosterone concentration between Baseline and Week 6
Ramy czasowe: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair testosterone concentration from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair progesterone concentration between Baseline and Week 6
Ramy czasowe: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair progesterone concentration from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair corticosterone concentration between Baseline and Week 6
Ramy czasowe: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair corticosterone concentration from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair dehydroepiandrosterone (DHEA) concentration between Baseline and Week 6
Ramy czasowe: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair dehydroepiandrosterone (DHEA) concentration values from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair androstenedione concentration between Baseline and Week 6
Ramy czasowe: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair androstenedione concentration from Baseline to Week 6 |
Baseline, Week 6
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: Pervez Sultan, Stanford University
- Główny śledczy: Debra Kaysen, Stanford University
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 80498-2
- R01AT013866-01 (Grant/umowa NIH USA)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
Ramy czasowe udostępniania IPD
Beginning 9 months and ending 36 months following article publication.
Kryteria dostępu do udostępniania IPD
Wish whom? Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose. For what types of analysis? For individual participant data meta-analysis By what mechanism will data be made available? Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata. Information regarding submitting proposals and accessing data may be found at (Link to be provided).
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .